Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by the 2021 NSCLC treatment guidelines. This review outlines the research progress in the treatment of RET fusion NSCLC, identifies current challenges and describes proposals for improving the outlook for these patients.

Automated summary

Significant progress has been made in the treatment of driver gene-positive Non-Small Cell Lung Cancer (NSCLC) in recent years. RET fusion, which occurs in 0.7% to 2% of NSCLC cases, is associated with a younger age and never-smoker status. The use of pralsetinib and selpercatinib for RET fusion NSCLC is recommended according to the 2021 NSCLC treatment guidelines. This review summarizes the research progress, current challenges, and proposals for improving the outlook for patients with RET fusion NSCLC.